司美格鲁肽联合厄贝沙坦治疗早期糖尿病肾病的临床研究  

Clinical Study of Smeglutide Combined with Irbesartan in the Treatment of Early Diabetic Nephropathy

作　　者：龙玉如 朱静 秦楠楠 LONG Yuru;ZHU Jing;QIN Nannan(Department of Endocrinology and Nephrology,Suining Hospital of Traditional Chinese Medicine,Xuzhou 221200,Jiangsu,China)

机构地区：[1]睢宁县中医院内分泌肾内科,江苏徐州221200

出　　处：《糖尿病新世界》2024年第11期190-194,共5页Diabetes New World

摘　　要：目的探究在早期糖尿病肾病(diabetic nephropathy,DN)治疗中联合使用司美格鲁肽与厄贝沙坦的临床疗效。方法选取2022年6月—2023年12月睢宁县中医院收治的80例早期DN患者为研究对象,按照治疗方法不同分为两组,各40例。对照组给予厄贝沙坦治疗,观察组给予司美格鲁肽联合厄贝沙坦治疗。比较两组患者的临床效果、血糖指标[空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2-hour postprandial plasma glucose,2 hPG)及糖化血红蛋白(glycated hemoglobin A1c,HbA1c)]、肾功能指标[血肌酐(serum creati⁃nine,Scr)、尿素氮(blood urea nitrogen,BUN)和24 h尿蛋白定量]以及炎性因子水平[肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)和单核细胞趋化蛋白-1(monocyte chemotactic protein 1,MCP-1)]变化情况。结果对照组治疗总有效率为82.50%(33/40),低于观察组的97.50%(39/40),差异有统计学意义(P<0.05)。观察组FPG、2 hPG、HbA1c、Scr、BUN、24 h尿蛋白定量、TNF-α、IL-6和MCP-1水平均低于对照组,差异有统计学意义(P均<0.05)。结论在早期DN的治疗中,将司美格鲁肽与厄贝沙坦联合使用可提高临床治疗效果,有效降低患者的血糖水平和炎症因子水平,并改善肾功能。Objective To explore the clinical efficacy of combined use of semeglutide and irbesartan in the treatment of early diabetic nephropathy(DN).Methods A total of 80 patients with early DN admitted to Suining Hospital of Tra-ditional Chinese Medicine from June 2022 to December 2023 were selected as the research objects.According to dif-ferent treatment methods,they were divided into two groups,with 40 cases in each group.The control group was treated with irbesartan,and the observation group was treated with semaglutide combined with irbesartan.The clinical effects,blood glucose indexes[fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG)and gly-cated hemoglobin A1c(HbA1c)],renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN)and 24 h urine protein quantification]and inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and monocyte chemotactic protein 1(MCP-1)]were compared between the two groups.Results The total effective rate of the control group was 82.50%(33/40),which was lower than 97.50%(39/40)of the observation group,and the dif-ference was statistically significant(P<0.05).The levels of FPG、2 hPG、HbA1c、Scr、BUN、24 h urinary protein、TNF-α、IL-6 and MCP-1 in observation group were lower than those in control group,and the differences were sig-nificant(all P<0.05).Conclusion In the treatment of early DN,the combination of semaglutide and irbesartan can im-prove the clinical treatment effect,effectively reduce the level of blood glucose and inflammatory factors,and improve renal function.

关 键 词：司美格鲁肽 厄贝沙坦 早期糖尿病肾病 肾功能指标 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]